The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.
Some of our ongoing projects include:
- Investigation of the GITR pathway as it relates to regulatory and effector T cells.
- Use of OX40 agonists alone and in combination with chemotherapy.
- Exploration of the role of myeloid derived suppressor cells in tumor immunity.
We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.
Jedd D. Wolchok, MD, PhD
Chief, Melanoma and Immunotherapeutics Service; Member and Attending Physician
Professor
Research Focus
Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.Education
- Princeton University, Princeton, NJ BA
- New York University, New York, NY MS
- New York University, New York, NY PhD
- New York University, New York, NY MD
- Clinical Office 646-888-2395
- Lab Phone: 646-888-2585 (Laboratory Office)
Lab Members
Jedd D. Wolchok
Lab Head
Taha Merghoub
Attending Biologist/ Co Lab Head
Beatrice Yin
Research Lab Manager
Daniel Hirschhorn-Cymerman
Senior Research Scientist
Sadna Budhu
Research Associate
Roberta Zappasodi
Research Scholar
Dmitriy Zamarin
Assistant Attending Physician
Alexander Lesokhin
Assistant Member
Margaret K. Callahan
Assistant Attending, Department of Medicine
Michael Postow
Assistant Attending Physician
Shakuntala Tiwari
Senior Research Assistant
Cailian Liu
Senior Research Assistant
Hong Zhong
Senior Research Technician
Xia Yang
Senior Research Technician
Leila Sellam
Graduate Research Assistant
Chien-Huan Weng
Research Fellow
Mohsen Abu-Akeel
Research Technician
Allison Betof
Medical Oncology Fellow
Luis Felipe Campesato
Research Fellow
Hyejin Choi
Research Fellow
Andrew Chow
Medical Oncology Fellow
Lauren Dong
PhD Graduate Student
Claire Friedman
Medical Oncologist
Arnab Ghosh
Hematology and Medical Oncology Fellow
Rachel Giese
Research Fellow
Mathieu Gigoux
Research Fellow
Danny Khalil
Medical Oncologist
Levi Mark Bala Mangarin
Bioinformatics Technician
Judith Michels
Research Fellow
Stephane Pourpe
Research Assistant
David Redmond
Bioinformatics Engineer IV
Bianca Santomasso
Neuro-Oncologist
Sara Schad
PhD Graduate Student
Nathan Suek
Research Technician
Tyler Walther
Research Technician
Publications
- Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26
- Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.
Selected Achievements
- The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)
